Login / Signup

Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective.

Timofey D LebedevRubina KousarBbumba PatrickMuhammad UsamaMeng-Kuei LeeMing TanXing-Guo Li
Published in: Cells (2023)
Epigenetic remodeling and metabolic reprogramming, two well-known cancer hallmarks, are highly intertwined. In addition to their abilities to confer cancer cell growth advantage, these alterations play a critical role in dynamically shaping the tumor microenvironment and antitumor immunity. Recent studies point toward the interplay between epigenetic regulation and metabolic rewiring as a potentially targetable Achilles' heel in cancer. In this review, we explore the key metabolic mechanisms that underpin the immunomodulatory role of AT-rich interaction domain 1A (ARID1A), the most frequently mutated epigenetic regulator across human cancers. We will summarize the recent advances in targeting ARID1A-deficient cancers by harnessing immune-metabolic vulnerability elicited by ARID1A deficiency to stimulate antitumor immune response, and ultimately, to improve patient outcome.
Keyphrases
  • papillary thyroid
  • immune response
  • squamous cell
  • childhood cancer
  • gene expression
  • lymph node metastasis
  • machine learning
  • drug delivery
  • dendritic cells
  • wild type
  • artificial intelligence
  • toll like receptor